Intratumoral administration of an oncolytic adenovirus led to dramatic intratumoral infiltration of both CD4+ and CD8+ lymphocytes and sensitized the M109 tumor to the treatment of anti–PD-1 or anti–PD-L1 antibodies [99]. The gene discussed is CD8A; the disease is neoplasm.